Bohnen Shane, the Senior Vice President and General Counsel of Bio-Techne Corp, has recently amended his stock ownership filing. This update, filed on November 2, 2026, is significant as it details transactions involving common stock and performance stock options.

The filing indicates that on August 15, 2026, Bohnen acquired 4,420 shares of common stock, bringing his total ownership to 11,773 shares. Furthermore, he disposed of 1,366 shares at a price of $72.40 each, leaving him with 10,407 shares following this transaction. Additionally, he exercised performance stock options for 11,929 shares, which were acquired without any cost, reducing his total ownership to 995 shares.

This amendment is crucial for understanding executive compensation and ownership structures within Bio-Techne, a company that operates in the biological products sector. The filing also highlights the board's discretionary vesting of certain performance options and restricted stock units, which can influence how stakeholders perceive the company's governance and executive incentives.

Background

Bio-Techne Corp, headquartered in Minneapolis, Minnesota, is a leading player in the biological products industry, specifically categorized under the SIC code 2836. The company focuses on developing and manufacturing products for life sciences research and clinical diagnostics. Recently, it has been active in filing various forms with the SEC, including Form 4 and its amendments, which provide insights into insider transactions and ownership changes.

What the Filing Says

The recent filing states, "On 8/15/2026, the Board of Directors authorized discretionary vesting for 995 performance options. The remainder of the performance options were forfeited." This indicates that the board is actively managing executive compensation through performance-based incentives.

Impact

This filing may affect various stakeholders, including investors, analysts, and competitors in the biological products industry. By disclosing these transactions, Bohnen Shane provides transparency regarding his ownership stake and the incentives tied to his role at Bio-Techne. Such disclosures can influence investor confidence and perceptions of corporate governance.

What's Next

The filing does not say what happens next.